Skip Nav Destination
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death
Issue Archive
Table of Contents
BLOOD COMMENTARIES
SPECIAL REPORT
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Clinical Trials & Observations
Frits van Rhee,Peter Voorhees,Angela Dispenzieri,Alexander Fosså,Gordan Srkalovic,Makoto Ide,Nikhil Munshi,Stephen Schey,Matthew Streetly,Sheila K. Pierson,Helen L. Partridge,Sudipto Mukherjee,Dustin Shilling,Katie Stone,Amy Greenway,Jason Ruth,Mary Jo Lechowicz,Shanmuganathan Chandrakasan,Raj Jayanthan,Elaine S. Jaffe,Heather Leitch,Naveen Pemmaraju,Amy Chadburn,Megan S. Lim,Kojo S. Elenitoba-Johnson,Vera Krymskaya,Aaron Goodman,Christian Hoffmann,Pier Luigi Zinzani,Simone Ferrero,Louis Terriou,Yasuharu Sato,David Simpson,Raymond Wong,Jean-Francois Rossi,Sunita Nasta,Kazuyuki Yoshizaki,Razelle Kurzrock,Thomas S. Uldrick,Corey Casper,Eric Oksenhendler,David C. Fajgenbaum
REVIEW ARTICLES
CLINICAL TRIALS AND OBSERVATIONS
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
CME
Clinical Trials & Observations
Matthieu Jestin,Ygal Benhamou,An-Sofie Schelpe,Elien Roose,François Provôt,Lionel Galicier,Miguel Hié,Claire Presne,Pascale Poullin,Alain Wynckel,Samir Saheb,Christophe Deligny,Aude Servais,Stéphane Girault,Yahsou Delmas,Tarik Kanouni,Alexandre Lautrette,Dominique Chauveau,Christiane Mousson,Pierre Perez,Jean-Michel Halimi,Anne Charvet-Rumpler,Mohamed Hamidou,Pascal Cathébras,Karen Vanhoorelbeke,Agnès Veyradier,Paul Coppo,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center,on behalf of the French Thrombotic Microangiopathies Reference Center
LYMPHOID NEOPLASIA
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
Michael A. Chapman,Jonathan Sive,John Ambrose,Claire Roddie,Nicholas Counsell,Anna Lach,Mahnaz Abbasian,Rakesh Popat,Jamie D. Cavenagh,Heather Oakervee,Matthew J. Streetly,Stephen Schey,Mickey Koh,Fenella Willis,Andres E. Virchis,Josephine Crowe,Michael F. Quinn,Gordon Cook,Charles R. Crawley,Guy Pratt,Mark Cook,Nivette Braganza,Toyin Adedayo,Paul Smith,Laura Clifton-Hadley,Roger G. Owen,Pieter Sonneveld,Jonathan J. Keats,Javier Herrero,Kwee Yong
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death
Clinical Trials & Observations
Brief Report
Shigeharu Ueki,Takahiro Tokunaga,Rossana C. N. Melo,Hidekazu Saito,Kohei Honda,Mineyo Fukuchi,Yasunori Konno,Masahide Takeda,Yohei Yamamoto,Makoto Hirokawa,Shigeharu Fujieda,Lisa A. Spencer,Peter F. Weller
TRANSPLANTATION
Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice
Vedran Radojcic,Katelyn Paz,Jooho Chung,Jing Du,Eric T. Perkey,Ryan Flynn,Sanja Ivcevic,Michael Zaiken,Ann Friedman,Minhong Yan,Maria A. Pletneva,Stefanie Sarantopoulos,Christian W. Siebel,Bruce R. Blazar,Ivan Maillard
There is a Blood Commentary on this article in this issue.
LETTERS TO BLOOD
BLOOD WORK
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
Galectin-10 forms Charcot-Leyden crystals (green, slender, bipyramidal structures) in nasal polyp tissue from a patient with eosinophilic chronic rhinosinusitis. The image shows a confocal image of galectin-10 (green), major basic protein (red), and DNA (blue) staining. See the article by Ueki et al on page 2183.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals